Clinical Trials Logo

Clinical Trial Summary

Sintilimab (R&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity. This study is a phase III clinical study of a three-week regimen of sintilimab combined with the XELOX+ bevacizumab for RAS-mutant metastatic colorectal cancer patients who had not received any treatment before. The purpose of this study is to explore the efficacy of sintilimab combined with XELOX + bevacizumab as first line therapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05171660
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact XUEFENG FANG
Phone 057187784718
Email xffang@zju.edu.cn
Status Recruiting
Phase Phase 3
Start date February 8, 2022
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03594448 - Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
Completed NCT03986541 - AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Completed NCT01570452 - Matrilysin Expression in Different Stages of Colorectal Tumors N/A
Recruiting NCT05354817 - Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin Phase 2
Recruiting NCT05576896 - Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory Phase 2
Completed NCT04715061 - Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments N/A
Terminated NCT03149679 - The p53 Colorectal Cancer Trial Phase 2
Completed NCT05550701 - Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
Enrolling by invitation NCT04149613 - Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
Completed NCT04425239 - Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer Phase 2
Completed NCT06329700 - Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
Recruiting NCT05382741 - Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial Phase 2
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Not yet recruiting NCT04917276 - Treatment Response Prediction System of mCRC Patients Based on CTC
Not yet recruiting NCT06296056 - Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care Phase 1
Recruiting NCT04714814 - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Not yet recruiting NCT05451719 - Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy Phase 2
Completed NCT03031444 - Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis Phase 2/Phase 3
Completed NCT05164419 - Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
Recruiting NCT05426005 - Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer Phase 1/Phase 2